Treatment of Systemic Mastocytosis with Recurrent Hypotension
Patients with indolent or smoldering systemic mastocytosis who experience recurrent hypotension
represent a distinct clinical situation requiring targeted symptom-focused management.
Clinical scenario
In indolent or smoldering systemic mastocytosis (ISM/SSM), recurrent hypotension reflects
episodic mediator release. Treatment goals in this population are primarily directed toward
anaphylaxis prevention and symptom control.
Treatment approach
The structured protocol for this scenario involves a combination of histamine-receptor
antagonists targeting both H1 and H2 pathways — but the specific selection, sequencing,
and management algorithm go beyond what can be summarised here.
Full regimen detail, dosing guidance, and clinical decision points are available via the link below.
References
DOI: 10.1002/ajh.26962
Treatment goals for ISM patients are primarily directed toward anaphylaxis prevention/symptom control/osteoporosis treatment.
H1- and H2-antagonists
View source ↗